Site Search

1. 81.
   AMP/assets/File/education/MIMP/Bone_Soft_Tissue_1.pdf?pass=46

   DDIT3 in 5%; TERT promoter mutations in ~60 ... FISH, NGS, RT-PCR >95%; PDGFD fusion in remaining cases. Tyrosine ... Fusion FISH, IHC, NGS 50-60%; 5-10% each ROS1 or NTRK3 fusion, rare ... fibrosarcoma (SEF)** EWSR1::CREB3L1 (> 60%) FUS::CREB3L2 Fusion FISH, IHC, NGS ... Mutation (activating) NGS, PCR ~75% KIT mutant, ~10% PDGFRA mutant. Tyrosine kinase inhibitor

   https://www.amp.org/AMP/assets/File/education/MIMP/Bone_Soft_Tissue_1.pdf?pass=4...
2. 82.
   AMP/assets/Joint Comments on GI Panels-First Coast-DL38227-8-11-2019-FINAL.pdf...

   viruses, and 5) C. difficile (https://moleculardiagnostics.bd.com/syndromic-solutions ... have reported sensitivity of 93%-100%.” In response to additional supporting ... have reported sensitivity of 93%-100%, but specificity is low because ... 2018 92(2):143-146 https://doi.org/10.1016/j.diagmicrobio ... November 2017, Pages e45–e80, https://doi.org/10.1093/cid/cix669

   https://www.amp.org/AMP/assets/Joint Comments on GI Panels-First Coast-DL38227-...
3. 83.
   AMP/assets/AMPComments-NCA-CRCBloodBasedBiomarkerTests-CAG-00454N-FINAL-11-15-20...

   than or equal to 74% and specificity greater than or equal to 90% in the detection of colorectal cancer compared to ... both sensitivity greater than or equal to 74% and specificity greater than or equal to 90% in the detection of colorectal cancer compared to ... e. FDA and the CLIA Program. Moreover, 1 https://www.cms.gov/medicare-coverage-database/details/ncd-

   https://www.amp.org/AMP/assets/AMPComments-NCA-CRCBloodBasedBiomarkerTests-CAG-0...
4. 84.
   AMP/assets/AMP Comments-VALID ACT-Oct192020-FINAL.pdf?pass=43

   the testing delays, approximately 35% of the professionals surveyed (both AMP ... been answered up front. In fact, 32% of the respondents said that they encountered ... supply chain shortages in the current 1 https://www.amp.org/advocacy/sars-cov-2-survey/2 https://www.nejm.org/doi/full/10.1056 ... of the 2009 H1N1 outbreak, 62% of the patients screened for H1N1

   https://www.amp.org/AMP/assets/AMP Comments-VALID ACT-Oct192020-FINAL.pdf?pass=4...
5. 85.
   AMP/assets/AMP Comments-VALID ACT-Oct192020-FINAL.pdf?pass=41

   the testing delays, approximately 35% of the professionals surveyed (both AMP ... been answered up front. In fact, 32% of the respondents said that they encountered ... supply chain shortages in the current 1 https://www.amp.org/advocacy/sars-cov-2-survey/2 https://www.nejm.org/doi/full/10.1056 ... of the 2009 H1N1 outbreak, 62% of the patients screened for H1N1

   https://www.amp.org/AMP/assets/AMP Comments-VALID ACT-Oct192020-FINAL.pdf?pass=4...
6. 86.
   AMP/assets/File/advocacy/AMPvFDA_Complaint_8.19.2024.pdf?pass=15

   Paper on [LDTs], https://www.fda.gov/media/102367/ ... and Innovation Act, available at https://tinyurl.com/DAIA-PR (Mar. ... DAIA Discussion Draft 2, at https://tinyurl.com/DAIA-PDF (2017 ... for first tissue/site agnostic indication, https://tinyurl.com/PembroPR (May 30, 2017 ... all dMMR tumors. Since approximately 3% of all cancerous tumors exhibit dMMR

   https://www.amp.org/AMP/assets/File/advocacy/AMPvFDA_Complaint_8.19.2024.pdf?pas...
7. 87.
   AMP/assets/File/advocacy/AMPvFDA_Complaint_8.19.2024.pdf?pass=95

   Paper on [LDTs], https://www.fda.gov/media/102367/ ... and Innovation Act, available at https://tinyurl.com/DAIA-PR (Mar. ... DAIA Discussion Draft 2, at https://tinyurl.com/DAIA-PDF (2017 ... for first tissue/site agnostic indication, https://tinyurl.com/PembroPR (May 30, 2017 ... all dMMR tumors. Since approximately 3% of all cancerous tumors exhibit dMMR

   https://www.amp.org/AMP/assets/File/advocacy/AMPvFDA_Complaint_8.19.2024.pdf?pas...
8. 88.
   AMP/assets/AMP_Comments_PFSCY2019_CMS-1693-P_9-10-2018FINAL.pdf?pass=67

   Further, CMS reported that 37% of reporting labs were exempt from ... infectious diseases) on the CLFS, 57% decreased in value while 20% increased from their 2017 National Limitation ... Ninety molecular tests (or roughly 40%) decreased by 30% or more. Moreover, there are many ... To Ensure Data Quality.” OIG, July 2018, https://oig.hhs.gov/oei/reports/oei-09

   https://www.amp.org/AMP/assets/AMP_Comments_PFSCY2019_CMS-1693-P_9-10-2018FINAL....
9. 89.
   AMP/assets/File/education/MIMP/Bioinformatics_FILE_Formats_one.pdf?pass=55

   Accuracy + 10 1 in 10 90% 5 20 1 in 100 99% ? 30 1 in 1,000 99.9% I 40 1 in 10,000 99.99% Example 2: @NB551591:7:HJT5CBGX9:1:11101:9719:1040 1:N:0:CATCAAGT ... 1 in 1,587 99.94% 0.00063 E 36 1 in 4,000 99.98% 0.00025 References 1. https://support.illumina.com/bulletins/2016/04/fastq-files-explained.html 2. http://drive5.com

   https://www.amp.org/AMP/assets/File/education/MIMP/Bioinformatics_FILE_Formats_o...
10. 90.
    AMP/assets/File/advocacy/AMP_Response_to_Cures_3_0_RFI.pdf?pass=68

    outbreaks, including the increasingly 1 https://www.amp.org/advocacy/sars-cov-2-survey/ ... 2https://www.amp.org/AMP/assets/File/advocacy/AMP%20Future%20Pandemic%20White%20Paper%20Response.pdf?pass=29 During the COVID-19 pandemic ... Breakthrough Products Act of 2023, exclude clinical 3 2 https://www.hhs.gov/ohrp/regulations-and-policy/guidance/ohrp-

    https://www.amp.org/AMP/assets/File/advocacy/AMP_Response_to_Cures_3_0_RFI.pdf?p...